Background Accurate outcome prediction in neuroblastoma, which is necessary to enable
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …

Accurate assessment of neuroblastoma outcome prediction remains challenging. Therefore,
this study aims at establishing novel prognostic tumor DNA methylation biomarkers. In total …

Aim: To define the DNA methylation landscape of neuroblastoma and its clinicopathological
impact. Materials & methods: Microarray DNA methylation data were analyzed and …

Neuroblastoma is a very heterogeneous tumor of childhood. The clinical spectra range from
very aggressive metastatic disease to spontaneous regression, even without therapy …

Background Neuroblastoma is the most common malignancy in infancy, accounting for 15%
of childhood cancer deaths. Outcome for the high-risk disease remains poor. DNA …

Neuroblastoma (NB) pathogenesis has been reported to be closely associated with
numerous genetic alterations. However, underlying DNA methylation patterns have not been …

The downregulation of specific genes through DNA hypermethylation is a major hallmark of
cancer, although the extent and genomic distribution of hypermethylation occurring within …

Background Epigenetic mechanisms such as DNA methylation and histone modifications
are important regulators of gene expression and are frequently involved in silencing tumor …

The broad clinical spectrum of neuroblastoma ranges from spontaneous regression to rapid
progression despite intensive multimodal therapy. This diversity is not fully explained by …

Objective: To identify a specific hypermethylated molecular biomarker for human malignant
glioblastoma prognosis. Materials and Methods: Genome-wide methylation profiling was …